Research programme: 1 phosphatidylinositol 3-kinase inhibitors - OncothyreonAlternative Names: PX-867
Latest Information Update: 04 Feb 2011
At a glance
- Originator Oncothyreon
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Signal transduction pathway modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Feb 2011 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)